Rabia Khan is the Founder and CEO of Serna Bio, an AI-enabled drug discovery company developing small molecules that modulate translation and splicing to treat diseases with high unmet need. Serna Bio operates at the intersection of synthetic biology, machine learning, and massively multiplexed screening to drug the transcriptome in novel ways.
By integrating in vitro assays with machine learning, the team maps functional RNA structures across the transcriptome and has built the world’s largest database of druggable RNA motifs—fueling internal programs and external collaborations.
Rabia earned her PhD in Human Genetics from McGill University and an MBA from Concordia. Prior to founding Serna Bio, she held leadership roles across biotech and AI-driven drug discovery, including VP of Commercial Partnerships at Meta, Associate Director of Strategy and Planning at BenevolentAI, and Managing Director of Discovery Science at Sensyne Health. At Sensyne, she led scientific strategy, built out the discovery and data science teams, and drove major partnerships with Bayer, BMS, Roche, and Alexion.
Get the latest from The Biotech Startups Podcast delivered straight to your inbox. Subscribe for weekly updates on new episodes—featuring expert insights, actionable advice, and stories from across the biotech industry.
